跳至主要内容
临床试验/NCT06406790
NCT06406790招募中4 期

A Multicenter, Single-Blind, Prospective Randomized Post-Approval Study Comparing the Safety and Effectiveness of CraniSeal Dural Sealant to DuraSeal Dural Sealant for Dural Sealing in Elective Cranial Surgery

Pramand LLC11 个研究点 分布在 1 个国家目标入组 224 人开始时间: 2024年5月29日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
招募中
发起方
Pramand LLC
入组人数
224
试验地点
11
主要终点
Absence of CSF Leaks

研究概览

简要总结

To collect post-approval data comparing the safety and effectiveness of CraniSeal Dural Sealant to DuraSeal Dural Sealant. The study has been powered specifically to determine whether the CraniSeal device when used as an adjunct to sutured dural closure following elective cranial surgery is no worse than (i.e., non-inferior) to the DuraSeal device with respect to proportion of subjects free from post-operative cerebrospinal fluid (CSF) leaks. Additional safety outcomes (i.e., surgical site infections and adverse events/device-related adverse events) will also be captured and compared.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Participant will be blinded to dural sealant until they have completed 90 day study.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • General Inclusion Criteria:
  • Patient is ≥ 18 years of age
  • Patient is scheduled for an elective infratentorial or supratentorial cranial procedure under general anesthesia that entails a dural incision
  • Patient requires a procedure involving surgical wound classification Class I/Clean
  • Patient signs a written Informed Consent form to participate in the study, prior to any study mandated determinations or procedures.
  • Patients who are able to comply with study requirements.

排除标准

  • Patient requires a procedure involving translabyrinthine, transsphenoidal, transoral and/ or any procedure that penetrates the air sinus or mastoid air cells; superficial penetration of air cells are not excluded
  • Patient has had a prior intracranial neurosurgical procedure in the same anatomical location
  • Patient with diagnosis of severely altered renal (creatinine levels > 2.0 mg/dL) or hepatic (total bilirubin > 2.5 mg/dL) function
  • Patient diagnosed with a compromised immune system or autoimmune disease (WBC count less than 4000/uL or greater than 20,000/uL)
  • Patients undergoing cranial procedures involving petrous bone drilling
  • Patients with traumatic injuries to the head or dural disease in planned dural closure area
  • Patients who are pregnant or lactating
  • Patient with an active infection
  • Patient is undergoing cranial procedures involving non-autologous duraplasty material that are not collagen based
  • Patients requiring re-opening of planned surgical area within 90 days after surgery.
  • Patient with a known allergy to FD&C Blue #1 dye
  • Patient is not able to tolerate multiple Valsalva maneuvers, or transient elevation of CSF pressure during Valsalva maneuvers is not possible (e.g. the presence of a temporary or permanent CSF shunt
  • Presence of hydrocephalus
  • Patient with a diagnosis of uncontrolled diabetes (e.g., persistent HbA1c elevation of >9% despite standard diabetes care),
  • Patient has a documented, uncorrectable clinically significant coagulopathy (e.g., PTT>37 seconds or INR >1.5 units)
  • Patient is not likely to comply with the follow-up evaluation schedule.
  • Contraindications to both an MRI and CT scan.
  • Patients participating in any investigational device study within 30 days or currently receiving an investigational drug/biologic therapy. (Observational studies on FDA approved products are not applicable)
  • Patients diagnosed with Meningiomatosis (multiple meningiomas)

研究组 & 干预措施

CraniSeal

Experimental

CraniSeal

干预措施: CraniSeal (Device)

DuraSeal

Active Comparator

DuraSeal

干预措施: DuraSeal (Device)

结局指标

主要结局

Absence of CSF Leaks

时间窗: 90 days

absence of CSF leaks on study

次要结局

未报告次要终点

研究者

发起方
Pramand LLC
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验

CraniSeal Post Approval Study | 临床试验